尊龙凯时人生就博官网登录,ag尊龙凯时，尊龙凯时

    |
    EN
    |
    EN
    EN

    • 业务咨询

      中国：

      Email: marketing@clwgov.com

      业务咨询专线：400-780-8018

      （仅限服务咨询，其他事宜请拨打川沙总部电话）

      川沙总部电话: +86 (21) 5859-1500

      海外：

      +1(626)986-9880(U.S. - West Coast)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在线留言×
    点击切换
    Customer Center
    客户中心

    CAR-T疗法主要针对白血病与恶性淋巴瘤，此研究中构建沉默PD-1的shRNA载体质粒，测序后质粒的鉴定通过尊龙凯时人生就博官网登录,ag尊龙凯时，尊龙凯时进行

    2023-06-28
    |
    访问量：

    12-The-plasmids-sequenced-were-fully-identified-by-Medicilon-1.jpg

    Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.

    Reference

    Jing-E Zhou, et al. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft. Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339.

    相关新闻
    友情链接: